Full history for every metric is available with a Kvantra account

Stock profile
Medpace Holdings, Inc. logo

Medpace Holdings, Inc. (MEDP)

Country: United States of AmericaSector: HealthcareIndustry: Medical - Diagnostics & ResearchExchange: NASDAQ
P/E TTM
33.8
History
P/E NTM
31.2
Market cap
17.08B
Currency USD
KvantraRankAbout48
IValue20
IIQuality95
IIIMomentum28
Current price
610.54 USD-3.70%
Close 20 Nov 2026
Interval
Benchmarks

Key financial summary

Financials in USD
202020212022202320242025TTM2026E
Total revenue$m9261,1421,4601,8862,1092,5302,8382,850
Operating profit$m535607
Net profit$m145182245283404451518535
EPS reported$15.2818.04
Operating cashflow per share$24.7325.88
Capex per share$1.091.98
FCF per share$23.6423.89
Free cash flow$m682668
Net debt$m-360-559
Book value equity$m459585
Book value per share$15.5520.62
Number of sharesm29.5328.37
DPS (TTM paid)$0.000.00

Financial summary

Financials in USD
202020212022202320242025TTM2026E
Value
P/E TTMx36.7633.84
P/B LTMx35.2929.20
P/S LTMx6.406.02
P/FCF LTMx23.7625.58
EV/EBITDA LTMx27.7725.67
EV/Sales LTMx6.265.82
Earnings Yield LTM%2.72%2.96%
FCF Yield%4.21%3.91%
Quality
ROE%98.27%99.76%
ROIC%67.94%62.17%
Operating margin%21.14%21.39%
Gross margin%30.06%29.14%
FCF/Sales%26.95%23.52%
Growth and momentum
EPS Growth YoY%+20.98%+26.07%
Sales Growth YoY%+19.97%+20.35%
Net Income Growth YoY%+11.56%+19.59%
FCF Growth%+19.15%-5.11%
Operating Profit Growth%+19.71%+19.74%
Dividend and capital structure
Dividend Yield%0.00%0.00%
Dividend Growth%0.00%0.00%
Payout Ratio%0.00%0.00%
FCF/Debtx4.984.57
Net Debt/EBITDAx-0.63-0.87
EBIT/Net interestx--
Net debt/market cap%-2.22%-3.27%
Net debt/Equityx-0.78-0.96
Gross debt/equityx0.300.25

ETFs that hold Medpace Holdings

FundTickerPosition#Weight
Invesco S&P MidCap Quality ETFXMHQ33.77%
Nuveen ESG Small-Cap ETFNUSC90.87%
First Trust Large Cap Growth AlphaDEX FundFTC41.00%
First Trust Health Care AlphaDEX FundFXH52.36%
Janus Henderson Small/Mid Cap Growth Alpha ETFJSMD61.93%
TD Q U.S. Small-Mid-Cap Equity ETFTQSM.TO61.22%
Invesco S&P MidCap 400 GARP ETFGRPM92.42%
First Trust Multi Cap Growth AlphaDEX FundFAD40.49%
Congress SMID Growth ETFCSMD53.15%
Invesco S&P MidCap 400 Pure Growth ETFRFG22.26%

Funds with Medpace Holdings among their ten largest holdings, largest fund first.

Price target estimates

Low estimate
High estimate
Price consensus
Last year average price target
Current price610.54 USD
Return Potential

Based on consensus from external analysts. Not Kvantra's opinion.

Ratings

Strong Buy
Buy
Hold
Sell
Strong Sell
Number of covering analysts

Based on consensus from external analysts. Not Kvantra's opinion.

ESG

Metric202420252026
ESG-score
Environmental score
Social score
Governance score
Risk rating

Company overview

Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance. Medpace's services include designing development programs, coordinating central laboratory functions, managing projects, navigating regulatory processes, overseeing clinical trials, handling data management and analytics, ensuring pharmacovigilance, aiding with new drug application submissions, and providing ongoing post-marketing clinical support. Furthermore, the company offers specialized bio-analytical laboratory testing, conducts clinical human pharmacology studies, provides imaging services, and delivers expert electrocardiography (ECG) reading for clinical research.

Trades inUSD

Similar companies

For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.

Medpace Holdings, Inc. (MEDP)

MEDP · NASDAQ · Healthcare
610.54 USD-3.70%
Sign up to track this stock
Benchmarks
KvantraRank48
Market cap17.08B
P/E NTM31.2
P/E TTM33.8
KvantraRank?48 / 100
Value
20
Quality
95
Momentum
28
Financialsin USD
20242025TTM2026E
ETFs that hold Medpace Holdings
FundTickerPosition#Weight
Invesco S&P MidCap Quality ETFXMHQ33.77%
Nuveen ESG Small-Cap ETFNUSC90.87%
First Trust Large Cap Growth AlphaDEX FundFTC41.00%
First Trust Health Care AlphaDEX FundFXH52.36%
Janus Henderson Small/Mid Cap Growth Alpha ETFJSMD61.93%
TD Q U.S. Small-Mid-Cap Equity ETFTQSM.TO61.22%
Invesco S&P MidCap 400 GARP ETFGRPM92.42%
First Trust Multi Cap Growth AlphaDEX FundFAD40.49%
Congress SMID Growth ETFCSMD53.15%
Invesco S&P MidCap 400 Pure Growth ETFRFG22.26%

Funds with Medpace Holdings among their ten largest holdings, largest fund first.

Analyst target
Consensus
Current610.54 USD
Upside
Price consensus
Last year average price target
Current price610.54 USD
Return Potential

Consensus from external analysts. Not Kvantra's opinion.

Ratings
Strong Buy
Buy
Hold
Sell
Strong Sell

Based on consensus from external analysts. Not Kvantra's opinion.

ESG
202420252026
ESG-score
Environmental score
Social score
Governance score
Risk rating
About

Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance. Medpace's services include designing development programs, coordinating central laboratory functions, managing projects, navigating regulatory processes, overseeing clinical trials, handling data management and analytics, ensuring pharmacovigilance, aiding with new drug application submissions, and providing ongoing post-marketing clinical support. Furthermore, the company offers specialized bio-analytical laboratory testing, conducts clinical human pharmacology studies, provides imaging services, and delivers expert electrocardiography (ECG) reading for clinical research.

IndustryMedical - Diagnostics & Research
Trades inUSD

For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.

Unlock all fundamental data

Sign up for Free

Unlock all fundamental data

Sign up for Free